- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00671294
Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia.
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Determine the Safety and Efficacy of TAK-375 in Elderly Subjects With Chronic Insomnia.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Insomnia is characterized by a complaint of difficulties initiating and maintaining sleep or of nonrestorative and non-refreshing sleep. Transient insomnia affects approximately one-third to one-half of the US population, based on the results of 2 surveys of representative samples of the adult US population conducted by the Gallup Organization in which respondents were asked if they had .ever had difficulty sleeping. Based on reports of regular or frequent sleep difficulty, results from the same studies suggest that approximately one-tenth of the US population experiences chronic insomnia. The ideal treatment for insomnia would reduce the latency to onset of sleep and increase total sleep time, without a negative impact on sleep architecture and without safety concerns or next-day effects.
Ramelteon is a melatonin-1 receptor agonist under global development by Takeda Chemical Industries, Ltd., Osaka, Japan, for the treatment of transient and chronic insomnia and for the treatment of Circadian Rhythm Sleep Disorders.
Participation in this study is anticipated to be about 2 months.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Arkansas
-
Hot Springs,, Arkansas, United States
-
-
California
-
Irvine, California, United States
-
Palm Springs, California, United States
-
San Diego, California, United States
-
-
Florida
-
Brandon, Florida, United States
-
Miami, Florida, United States
-
Naples, Florida, United States
-
Pembroke Pines, Florida, United States
-
St. Petersburg, Florida, United States
-
-
Georgia
-
Atlanta, Georgia, United States
-
-
Kansas
-
Overland Park, Kansas, United States
-
-
Kentucky
-
Crestview Hills, Kentucky, United States
-
-
Michigan
-
Troy, Michigan, United States
-
-
Missouri
-
St. Louis, Missouri, United States
-
-
North Carolina
-
Winston-Salem, North Carolina, United States
-
-
Ohio
-
Cincinnati, Ohio, United States
-
Toledo, Ohio, United States
-
-
Texas
-
Houston, Texas, United States
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Male or a post-menopausal female.
- Primary insomnia as defined by the Diagnostic and Statistical Manual of Mental Disorders, Text Revision for at least 3 months and as defined by subjective sleep latency greater than or equal to 30 minutes, subjective total sleep time less than or equal to 6.5 hours per night, and daytime complaint(s) associated with disturbed sleep.
- Mean latency of greater than or equal to 20 minutes per polysomnography on two consecutive screening nights with neither night less than 15 minutes. Also, a mean of 60 minutes of wake time during the 480 minutes in bed across two nights with no night less than 45 minutes.
- Habitual bedtime is between 8:30 p.m. and 12:00 a.m.
- Body mass index between 18 and 34, inclusive.
Exclusion Criteria
- Known hypersensitivity to Ramelteon or related compounds, including melatonin.
- Previously participated in a study involving Ramelteon.
- Participated in any other investigational study and/or taken any investigational drug within 30 days or five half-lives prior to Day 1 of single-blind study medication, whichever is longer.
- Sleep schedule changes required by employment (eg, shift worker) within three months prior to Day 1 of single-blind study medication, or has flown across greater than three time zones within seven days prior to screening.
- Participated in a weight loss program or has substantially altered their exercise routine within 30 days prior to Day 1 of single-blind study medication.
- Ever had a history of seizures, sleep apnea, chronic obstructive pulmonary disease, schizophrenia, bipolar disorder, mental retardation, or cognitive disorder.
- History of psychiatric disorder (including anxiety or depression) within the past 12 months.
- History of drug addiction or drug abuse within the past 12 months.
- History of alcohol abuse within the past 12 months.
- Had an acute clinically significant illness, as determined by the investigator, within 30 days prior to Day 1 of single-blind study medication.
- Current significant neurological (including cognitive and psychiatric disorders), hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematologic, or metabolic disease, unless currently controlled and stable with protocol-allowed medication 30 days prior to Day 1 of single-blind study medication.
- Used tobacco products within 90 days prior to Day 1 of single-blind study medication.
- Used melatonin, or other drugs or supplements known to affect sleep/wake function, or has consumed grapefruit or grapefruit juice within 5 days (or 5 half lives, whichever is longer) prior to Day 1 of single-blind study medication.
- Used any central nervous system medication within 3 weeks (or 5 half lives of the drug, whichever is longer) prior to Day 1 of singleblind study medication. These medications must not have been used to treat psychiatric disorders.
- Any clinically important abnormal finding as determined by a medical history, physical examination, electrocardiogram, or clinical laboratory tests, as determined by the investigator.
- Positive hepatitis panel including anti-hepatitis A virus (only immunoglobulin M is exclusionary), anti- hepatitis B surface (except in subjects who have received hepatitis B virus vaccination), hepatitis B surface antigen, anti- hepatitis B core (only immunoglobulin M is exclusionary), or anti-hepatitis C virus.
- Positive urine drug screen including alcohol at screening and each check-in or a positive breathalyzer test at each check-in.
- Apnea hypopnea index (per hour of sleep) greater than 15 as seen on polysonography, on the first night of the polysonography screening.
- Periodic leg movement with arousal index (per hour of sleep) greater than 20 as seen on polysonography, on the first night of polysonography screening.
- Any additional condition(s) that in the Investigator.s opinion would: a) affect sleep/wake function, b) prohibit the subject from completing the study, or c) not be in the best interest of the subject to participate in the study.
Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:
Within 3 weeks prior to Day 1 of single-blind study medication and during the study:
- anxiolytics
- hypnotics
- antidepressants
- anticonvulsants
- sedating H1 antihistamines
- systemic steroids
- respiratory stimulants (eg, theophylline) and decongestants
- over-the counter and prescription stimulants
- over-the counter and prescription diet aids
- central nervous system active drugs (including herbal preparations with central nervous system effects)
- narcotic analgesics
- beta blockers
- St. John.s wort
- kava-kava
- gingko biloba, any other supplements
Within 5 days prior to Day 1 of single-blind study medication and during the study:
- melatonin, or other drugs or supplements known to affect sleep/wake function.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ramelteon and Placebo QD (9 possible combinations total)
|
Randomized sequence over two consecutive nights for a total of three treatment periods to include the following: Ramelteon 4 mg, tablets, orally over two nights Ramelteon 8 mg, tablets, orally over two nights Ramelteon placebo-matching tablets, orally over two nights
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean latency to persistent sleep of 2-night per polysomnogram recordings, from nights 1 and 2 of each Treatment Period.
Time Frame: Crossover Periods 1, 2, and 3 on Nights 1 and 2 or Final Visit.
|
Crossover Periods 1, 2, and 3 on Nights 1 and 2 or Final Visit.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Total Sleep Time.
Time Frame: Crossover Periods 1, 2, and 3 on Nights 1 and 2 or Final Visit.
|
Crossover Periods 1, 2, and 3 on Nights 1 and 2 or Final Visit.
|
Sleep Efficiency.
Time Frame: Crossover Periods 1, 2, and 3 on Nights 1 and 2 or Final Visit.
|
Crossover Periods 1, 2, and 3 on Nights 1 and 2 or Final Visit.
|
Wake Time after Sleep Onset.
Time Frame: Crossover Periods 1, 2, and 3 on Nights 1 and 2 or Final Visit.
|
Crossover Periods 1, 2, and 3 on Nights 1 and 2 or Final Visit.
|
Number of Awakenings after Persistent Sleep Onset.
Time Frame: Crossover Periods 1, 2, and 3 on Nights 1 and 2 or Final Visit.
|
Crossover Periods 1, 2, and 3 on Nights 1 and 2 or Final Visit.
|
Subjective Sleep Latency.
Time Frame: Crossover Periods 1, 2, and 3 on Mornings 2 and 3 or Final Visit.
|
Crossover Periods 1, 2, and 3 on Mornings 2 and 3 or Final Visit.
|
Subjective Total Sleep Time.
Time Frame: Crossover Periods 1, 2, and 3 on Mornings 2 and 3 or Final Visit.
|
Crossover Periods 1, 2, and 3 on Mornings 2 and 3 or Final Visit.
|
Subjective Wake Time after Sleep Onset.
Time Frame: Crossover Periods 1, 2, and 3 on Mornings 2 and 3 or Final Visit.
|
Crossover Periods 1, 2, and 3 on Mornings 2 and 3 or Final Visit.
|
Subjective Number of Awakenings.
Time Frame: Crossover Periods 1, 2, and 3 on Mornings 2 and 3 or Final Visit.
|
Crossover Periods 1, 2, and 3 on Mornings 2 and 3 or Final Visit.
|
Subjective Ease of Falling Back to Sleep after Awakening.
Time Frame: Crossover Periods 1, 2, and 3 on Mornings 2 and 3 or Final Visit.
|
Crossover Periods 1, 2, and 3 on Mornings 2 and 3 or Final Visit.
|
Subjective Sleep Quality.
Time Frame: Crossover Periods 1, 2, and 3 on Mornings 2 and 3 or Final Visit.
|
Crossover Periods 1, 2, and 3 on Mornings 2 and 3 or Final Visit.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Wang-Weigand S, McCue M, Ogrinc F, Mini L. Effects of ramelteon 8 mg on objective sleep latency in adults with chronic insomnia on nights 1 and 2: pooled analysis. Curr Med Res Opin. 2009 May;25(5):1209-13. doi: 10.1185/03007990902858527.
- Roth T, Seiden D, Wang-Weigand S, Zhang J. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin. 2007 May;23(5):1005-14. doi: 10.1185/030079907x178874.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 01-02-TL-375-017
- U1111-1114-8272 (Registry Identifier: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Insomnia
-
University of AarhusTrygFonden, Denmark; Enversion A/SActive, not recruiting
-
Posit Science CorporationCompletedInsomnia ChronicUnited States
-
Jun SongUnknown
-
University of ManitobaCompleted
-
University of Missouri-ColumbiaUniversity of FloridaCompleted
-
University of AarhusTrygFonden, Denmark; Enversion A/SCompleted
-
University of TromsoUniversity Hospital of North Norway; Diakonhjemmet HospitalNot yet recruitingPain, Chronic | Insomnia Chronic | Insomnia Due to Medical ConditionNorway
-
University of Missouri-ColumbiaCompletedPain, Chronic | Insomnia ChronicUnited States
-
Diakonhjemmet HospitalActive, not recruitingSleep Disorder | Insomnia | Sleep Initiation and Maintenance Disorders | Chronic Disease | Sleep Disturbance | Insomnia Chronic | Insomnia Due to Medical Condition | Insomnia, PsychophysiologicalNorway
Clinical Trials on Ramelteon and Placebo (9 possible combinations total)
-
TakedaCompletedDrug AbuseUnited States
-
TakedaCompletedChronic Obstructive Pulmonary Disease | COPDUnited States
-
TakedaCompletedChronic Obstructive Pulmonary DiseaseUnited States
-
Massachusetts General HospitalTakedaCompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform DisordersUnited States
-
US Department of Veterans AffairsTakeda; Stanford UniversityCompletedInsomnia | Sleep Disorders | Spinal Cord Injury | TetraplegiaUnited States
-
Translational Research Center for Medical Innovation...Yoyogi Sleep Disorder Clinic, Foundation of Sleep and Health ScienceCompleted
-
Swedish Medical CenterTakedaTerminatedMigraine | Migraine Without Aura | Migraine With AuraUnited States
-
University of PennsylvaniaNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)Completed
-
Kessler FoundationUnknownBrain Injury | InsomniaUnited States